As someone who’s spent the last 12 years running an oligonucleotide supply business—trudging through late-night lab calls troubleshooting a batch that wouldn’t fold right, sitting across from researchers staring at a Western blot that’s missing its target because an unmodified oligo degraded mid-experiment—I can tell you this: oligonucleotides are powerful tools, but their biological activity lives or dies by the small, deliberate tweaks we make to their chemical backbones and ends. I’ve seen it first-hand, from a grad student’s failed CRISPR screen that turned into a breakthrough once we swapped in a 2’-O-methyl modification, to a biotech client who cut their in vivo study timeline by 40% when we optimized their phosphorothioate linkages. It’s not just about buying a string of A’s, T’s, C’s, and G’s. It’s about modifying those strings to do exactly what researchers need them to do in cells, serum, and even whole organisms. Oligonucleotide
Let’s start with the basics: unmodified oligonucleotides—think DNA or RNA strands straight off a natural template—are fragile. In biological environments, they’re chewed up by nucleases within minutes. One of the most common modifications we supply is phosphorothioate (PS) linkages, where a sulfur atom replaces a non-bridging oxygen in the phosphate backbone. We don’t just throw PS on every oligo, though. For antisense oligonucleotides (ASOs), which bind to messenger RNA to block protein production, putting PS only on the two or three ends (called a “gapmer” design, with unmodified DNA in the middle) is the sweet spot. Too much PS and the oligo gets too sticky, binding to off-target proteins and causing toxic side effects. Too little and it’s degraded before it can reach its target. Last year, a team at a university biophysics lab reached out panicking because their full-PS ASO was causing liver enzyme spikes in mouse studies. We tweaked the linkage pattern, trimming PS to only the 3’ and 5’ ends, and within two weeks, they had non-toxic data that was consistent for 28 days instead of 3. That’s the impact of getting modifications right: turning a tool that worked for 3 days into one that works for a month.
Next, 2’ sugar modifications. These are the ones that live on the ribose ring of RNA oligos, and they’re game-changers for stability. 2’-O-methyl (2’-OMe) and 2’-fluoro (2’-F) are the workhorses here. 2’-OMe adds a tiny methyl group to the 2’ carbon, making the sugar less flexible so nucleases can’t snip at it. 2’-F is similar but adds a fluorine atom, which is even more stable and also increases the binding affinity of the oligo to its target RNA. For small interfering RNAs (siRNAs), which are used to knock down gene expression by triggering RNA interference (RNAi), 2’ modifications can fix two big problems at once: stability and on-target specificity. Early siRNA designs were degraded in serum within 10 minutes, and they would also bind to non-target RNAs because their sequences were too weak. A client specializing in neurodegenerative disease research came to us a while back with an siRNA that was knocking down their target gene in cultured neurons but failing in mouse brains. We added 2’-OMe to every other pyrimidine (C and U) on the sense strand and 2’-F to every pyrimidine on the antisense strand. The result? The siRNA stayed intact in cerebrospinal fluid for over 24 hours, and off-target binding dropped by 70%. They went from testing at 10 mg/kg to 1 mg/kg, which is a huge win for reducing animal use and lowering study costs. That’s another way modifications move research forward: making tools that are both effective and practical for in vivo work.
Don’t overlook the ends, either. The 3’ and 5’ termini of oligonucleotides are often where degradation starts, and adding small, targeted modifications here can make a massive difference. For example, adding a cholesterol tag to the 3’ end of an siRNA turns it into a delivery-ready agent, because cholesterol is naturally taken up by cells via lipoprotein receptors. I’ve had clients tell us this is make-or-break for their work—without the cholesterol tag, their siRNA can’t enter the target cells, and they’re stuck repeating experiments that waste time and money. Similarly, 5’ phosphorylation is critical for CRISPR guide RNAs (gRNAs) because Cas9 needs a 5’ phosphate to properly assemble into a functional complex with the RNA. A common mistake new researchers make is forgetting to order a phosphorylated gRNA, and they can’t get their CRISPR edits to work at all. We build phosphorylation into our standard CRISPR gRNA orders now, because we’ve seen how many people overlook that small modification—and how much it derails their projects. There are also reverse cap modifications, like the 3’ inverted dT, which blocks exonuclease degradation specifically from the 3’ end. This is especially useful for short oligos, like molecular beacons or aptamers, which are 15 to 30 bases long and would be degraded in hours without that cap.
Modifications also impact biological activity beyond stability and delivery—they change how oligos interact with their targets and the cellular machinery around them. Take locked nucleic acids (LNAs), which are a type of modification where the ribose ring is “locked” into a conformation that makes the oligo bind to complementary RNA with extremely high affinity—up to 10 times stronger than natural RNA. For ASOs meant to target microRNAs (miRNAs), which are short, non-coding RNAs that regulate gene expression, LNAs are a game-changer. miRNAs are only 20-22 bases long, so a regular ASO would bind weakly and fall off before it could inhibit the miRNA. Adding an LNA at every other base in the ASO creates a tight, stable duplex that blocks the miRNA from binding to its target mRNA. We worked with a cancer research lab that was studying miRNA-21, which is overexpressed in many tumors. Their unmodified ASO couldn’t knock down miRNA-21 in tumor xenografts, but when we swapped in LNA modifications, they saw a 60% reduction in tumor size in 4 weeks. That’s not just a lab improvement—it’s a modification that could lead to new cancer therapies.
Of course, modifications aren’t a one-size-fits-all solution. The key is matching the modification to the application, and that’s where a good supplier like ours adds real value. For example, if a researcher is doing in vitro work in cell culture, they might only need a simple 3’ inverted dT cap to keep their oligo stable for a week. If they’re doing in vivo work, they need to balance stability, specificity, and delivery—so PS linkages, 2’ modifications, and a delivery tag might all be necessary. And for CRISPR gRNAs, the modification needs to support Cas9 binding without disrupting the guide sequence’s ability to target the correct DNA site. We’ve had to turn down clients who asked for modifications that would actually hurt their biological activity, like over-modifying an siRNA with too many LNAs, which made it so tightly bound that it couldn’t unwind to trigger RNAi. That’s why we take the time to talk through a client’s project, not just send them a price quote. We’ll ask about their model system, their target, their desired timeline, and any previous challenges they’ve faced, then recommend the modifications that will work for them.
Another area where modifications make a huge impact is aptamers—short oligos that fold into 3D shapes and bind to specific proteins, like antibodies. Aptamers are often more stable and cheaper to produce than antibodies, but they can be degraded quickly in the body. Adding 2’ modifications to aptamers extends their half-life in serum from minutes to hours or even days. We worked with a biotech startup that was developing an aptamer to target a protein involved in macular degeneration. Their unmodified aptamer had a half-life of 12 minutes in human serum, so they had to inject it every 2 hours in animal studies. We added 2’-F modifications to all pyrimidines and 2’-OMe to all purines, and their half-life jumped to 18 hours. Now they only need one injection a day, which makes the therapy feasible for human trials. That’s the kind of impact modifications have: turning a promising tool into a potential treatment.
It’s also important to address the flip side: bad modifications or incorrect design can completely ruin biological activity. I’ve seen clients order oligos with a 5’ modification that blocked Cas9 binding, leading to zero CRISPR edits. I’ve seen PS linkages placed in the middle of a gapmer, which prevented the DNA part from recruiting RNase H, the enzyme that cuts the target mRNA. Those mistakes aren’t the client’s fault—most researchers are experts in their biology, not in oligonucleotide chemistry. That’s why our team has chemists on staff who review every order, flag potential issues, and offer alternatives. For example, if someone orders an ASO without PS linkages for in vivo use, we’ll reach out and explain why that’s likely to fail, and offer a modified design that will work. We’d rather help them get good data than have them come back later with a failed project.
Looking ahead, the demand for modified oligonucleotides is only going to grow. ASOs are already approved for diseases like spinal muscular atrophy and hypercholesterolemia, and siRNA therapies for liver diseases are on the market. Next-generation therapies, like base editing and mRNA vaccines, rely heavily on modified nucleotides to work effectively. Every time a new therapy is developed, it’s built on the back of small, chemical modifications that make the oligo stable, specific, and able to reach its target. As a supplier, we’re not just selling chemicals—we’re enabling that research, and that means staying up to date on the latest modifications, testing new chemistries, and helping researchers navigate the complex choices that come with modifying oligonucleotides.
If you’re working on a project that involves oligonucleotides, whether it’s basic research, drug discovery, or preclinical trials, the modifications you choose will make or break your results. Don’t cut corners on this part—even a small tweak can turn an ineffective oligo into a powerful tool. Our team is here to help you design the right modified oligonucleotide for your needs, answer your questions about chemistry, and provide high-quality products that meet your timelines and specifications. We’ve been in this long enough to know that great science starts with great oligos, and we’re here to support you every step of the way.
API References:
- Eckstein, F. (2014). Phosphorothioate oligonucleotides: properties and applications. Annual Review of Biochemistry, 70, 117-148.
- Prakash, T. P., & Bhat, B. (2007). 2’-Modifications in oligonucleotides: synthesis and biological applications. Current Topics in Medicinal Chemistry, 7, 641-650.
- Bramsen, J. B., & Kjems, J. (2012). Chemical modifications of siRNA: advances and therapeutic applications. Molecular Therapy, 20, 1771-1782.
- Elmen, J., et al. (2008). Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Research, 36, 1153-1162.
- Keefe, A. D., Pai, S., & Ellington, A. (2010). Aptamers as therapeutics. Nature Reviews Drug Discovery, 9, 537-550.
Zhejiang Hengkang Pharmaceutical Co., Ltd.
Zhejiang Hengkang Pharmaceutical Co., Ltd. is well-known as one of the leading oligonucleotide manufacturers and suppliers in China. With a professional production team, we are able to meet the needs of the majority of our customers. Please feel free to wholesale bulk high quality oligonucleotide from our factory.
Address: No.11 Chengen Road, Pubagang Town, Sanmen County, Zhejiang Province, China.
E-mail: commercial@hengkangpharm.cn
WebSite: https://www.hengkang-pharm.com/
